iclaprim has been researched along with Gram-Positive Bacterial Infections in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Charrier, C; Hawser, S; Huang, DB | 1 |
| Corey, GR; Dryden, M; File, TM; Hadvary, P; Huang, DB; Shorr, AF; Torres, A; Wilcox, MH | 1 |
| Amin, F; Corey, GR; Dryden, M; File, TM; Heller, B; Holland, TL; Huang, DB; McLeroth, P; O'Riordan, W; Overcash, JS; Shukla, R; Torres, A; Wilcox, MH | 1 |
| Corey, GR; Huang, DB; Noviello, S | 1 |
| Cofer, C; Morgan, A; Stevens, DL | 1 |
| Schmidt, JM; Sincak, CA | 1 |
3 review(s) available for iclaprim and Gram-Positive Bacterial Infections
| Article | Year |
|---|---|
Iclaprim: a differentiated option for the treatment of skin and skin structure infections.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Folic Acid Antagonists; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Pyrimidines; Skin Diseases, Infectious | 2018 |
Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Gram-Positive Bacterial Infections; Humans; Pyrimidines; Skin Diseases, Bacterial; Soft Tissue Infections | 2009 |
Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Drug Resistance, Bacterial; Folic Acid Antagonists; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pyrimidines; Tetrahydrofolate Dehydrogenase | 2009 |
2 trial(s) available for iclaprim and Gram-Positive Bacterial Infections
| Article | Year |
|---|---|
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Double-Blind Method; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pneumonia; Pyrimidines; Treatment Outcome; Vancomycin | 2017 |
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Path
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pyrimidines; Skin; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2018 |
2 other study(ies) available for iclaprim and Gram-Positive Bacterial Infections
| Article | Year |
|---|---|
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Europe; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hospitalization; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrimidines; Staphylococcus aureus; Streptococcus; United States | 2009 |
Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.
Topics: Africa; Anti-Bacterial Agents; Asia; Europe; Folic Acid Antagonists; Global Health; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Latin America; Microbial Sensitivity Tests; Middle East; Population Surveillance; Pyrimidines; Skin; Skin Diseases, Infectious; Tetrahydrofolate Dehydrogenase; United States | 2020 |